Base de dados : MEDLINE
Pesquisa : K01.752.566.479.171.132.750.775 [Categoria DeCS]
Referências encontradas : 155 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 16 ir para página                         

  1 / 155 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29371211
[Au] Autor:Hey SP; Weijer C; Taljaard M; Kesselheim AS
[Ad] Endereço:Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, USA shey@bwh.harvard.edu.
[Ti] Título:Research ethics for emerging trial designs: does equipoise need to adapt?
[So] Source:BMJ;360:k226, 2018 01 25.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Ensaios Clínicos como Assunto/ética
Projetos de Pesquisa
Equipolência Terapêutica
[Mh] Termos MeSH secundário: Ensaios Clínicos como Assunto/métodos
Ética em Pesquisa
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180127
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k226


  2 / 155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28559034
[Au] Autor:Probst MA; Kanzaria HK; Schoenfeld EM; Menchine MD; Breslin M; Walsh C; Melnick ER; Hess EP
[Ad] Endereço:Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: mprobst@gmail.com.
[Ti] Título:Shared Decisionmaking in the Emergency Department: A Guiding Framework for Clinicians.
[So] Source:Ann Emerg Med;70(5):688-695, 2017 Nov.
[Is] ISSN:1097-6760
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Shared decisionmaking has been proposed as a method to promote active engagement of patients in emergency care decisions. Despite the recent attention shared decisionmaking has received in the emergency medicine community, including being the topic of the 2016 Academic Emergency Medicine Consensus Conference, misconceptions remain in regard to the precise meaning of the term, the process, and the conditions under which it is most likely to be valuable. With the help of a patient representative and an interaction designer, we developed a simple framework to illustrate how shared decisionmaking should be approached in clinical practice. We believe it should be the preferred or default approach to decisionmaking, except in clinical situations in which 3 factors interfere. These 3 factors are lack of clinical uncertainty or equipoise, patient decisionmaking ability, and time, all of which can render shared decisionmaking infeasible. Clinical equipoise refers to scenarios in which there are 2 or more medically reasonable management options. Patient decisionmaking ability refers to a patient's capacity and willingness to participate in his or her emergency care decisions. Time refers to the acuity of the clinical situation (which may require immediate action) and the time that the clinician has to devote to the shared decisionmaking conversation. In scenarios in which there is only one medically reasonable management option, informed consent is indicated, with compassionate persuasion used as appropriate. If time or patient capacity is lacking, physician-directed decisionmaking will occur. With this framework as the foundation, we discuss the process of shared decisionmaking and how it can be used in practice. Finally, we highlight 5 common misconceptions in regard to shared decisionmaking in the ED. With an improved understanding of shared decisionmaking, this approach should be used to facilitate the provision of high-quality, patient-centered emergency care.
[Mh] Termos MeSH primário: Tomada de Decisões
Medicina de Emergência/recursos humanos
Serviço Hospitalar de Emergência/organização & administração
Guias de Prática Clínica como Assunto/normas
[Mh] Termos MeSH secundário: Comunicação
Comportamento Cooperativo
Técnicas de Apoio para a Decisão
Medicina de Emergência/organização & administração
Serviço Hospitalar de Emergência/ética
Seres Humanos
Consentimento Livre e Esclarecido/legislação & jurisprudência
Masculino
Meia-Idade
Participação do Paciente/métodos
Assistência Centrada no Paciente/tendências
Relações Médico-Paciente
Médicos/ética
Médicos/psicologia
Equipolência Terapêutica
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170601
[St] Status:MEDLINE


  3 / 155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28170466
[Au] Autor:London AJ
[Ad] Endereço:Department of Philosophy, Carnegie Mellon University, Pittsburgh, Pennsylvania.
[Ti] Título:Equipoise in Research: Integrating Ethics and Science in Human Research.
[So] Source:JAMA;317(5):525-526, 2017 02 07.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Pesquisa
Equipolência Terapêutica
[Mh] Termos MeSH secundário: Ética Médica
Ética em Pesquisa
Seres Humanos
Projetos de Pesquisa
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170405
[Lr] Data última revisão:
170405
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.0016


  4 / 155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27918780
[Au] Autor:Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E; Heritage Study Investigators
[Ad] Endereço:University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco.
[Ti] Título:Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
[So] Source:JAMA;317(1):37-47, 2017 01 03.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)-positive metastatic breast cancer; a clinically effective biosimilar may help increase access to this therapy. Objective: To compare the overall response rate and assess the safety of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment for ERBB2-positive metastatic breast cancer. Design, Setting, and Participants: Multicenter, double-blind, randomized, parallel-group, phase 3 equivalence study in patients with metastatic breast cancer. From December 2012 to August 2015, 500 patients were randomized 1:1 to receive a proposed biosimilar or trastuzumab plus a taxane. Chemotherapy was administered for at least 24 weeks followed by antibody alone until unacceptable toxic effects or disease progression occurred. Interventions: Proposed biosimilar (n = 230) or trastuzumab (n = 228) with a taxane. Main Outcomes and Measures: The primary outcome was week 24 overall response rate (ORR) defined as complete or partial response. Equivalence boundaries were 0.81 to 1.24 with a 90% CI for ORR ratio (proposed biosimilar/trastuzumab) and -15% to 15% with a 95% CI for ORR difference. Secondary outcome measures included time to tumor progression, progression-free and overall survival at week 48, and adverse events. Results: Among 500 women randomized, the intention-to-treat population included 458 women (mean [SD] age, 53.6 [11.11] years) and the safety population included 493 women. The ORR was 69.6% (95% CI, 63.62%-75.51%) for the proposed biosimilar vs 64.0% (95% CI, 57.81%-70.26%) for trastuzumab. The ORR ratio (1.09; 90% CI, 0.974-1.211) and ORR difference (5.53; 95% CI, -3.08 to 14.04) were within the equivalence boundaries. At week 48, there was no statistically significant difference with the proposed biosimilar vs trastuzumab for time to tumor progression (41.3% vs 43.0%; -1.7%; 95% CI, -11.1% to 6.9%), progression-free survival (44.3% vs 44.7%; -0.4%; 95% CI, -9.4% to 8.7%), or overall survival (89.1% vs 85.1%; 4.0%; 95% CI, -2.1% to 10.3%). In the proposed biosimilar and trastuzumab groups, 239 (98.6%) and 233 (94.7%) had at least 1 adverse event, the most common including neutropenia (57.5% vs 53.3%), peripheral neuropathy (23.1% vs 24.8%), and diarrhea (20.6% vs 20.7%). Conclusions and Relevance: Among women with ERBB2-positive metastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks. Further study is needed to assess safety and long-term clinical outcome. Trial Registration: clinicaltrials.gov Identifier: NCT02472964; EudraCT Identifier: 2011-001965-42.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Medicamentos Biossimilares/uso terapêutico
Neoplasias da Mama/tratamento farmacológico
Receptor ErbB-2
Trastuzumab/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/efeitos adversos
Antineoplásicos/imunologia
Antineoplásicos Fitogênicos/efeitos adversos
Antineoplásicos Fitogênicos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Medicamentos Biossimilares/efeitos adversos
Neoplasias da Mama/química
Neoplasias da Mama/mortalidade
Neoplasias da Mama/patologia
Progressão da Doença
Método Duplo-Cego
Feminino
Seres Humanos
Análise de Intenção de Tratamento
Meia-Idade
Paclitaxel/efeitos adversos
Paclitaxel/uso terapêutico
Indução de Remissão
Análise de Sobrevida
Taxoides/efeitos adversos
Taxoides/uso terapêutico
Equipolência Terapêutica
Fatores de Tempo
Trastuzumab/efeitos adversos
Trastuzumab/imunologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Antineoplastic Agents, Phytogenic); 0 (Biosimilar Pharmaceuticals); 0 (Taxoids); 15H5577CQD (docetaxel); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2); P188ANX8CK (Trastuzumab); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170209
[Lr] Data última revisão:
170209
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161206
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2016.18305


  5 / 155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27537099
[Au] Autor:Greisen G; van Bel F
[Ad] Endereço:Neonatology, Rigshospitalet, Copenhagen, Denmark. gorm.greisen@regionh.dk.
[Ti] Título:Equipoise is necessary for randomising patients to clinical trials.
[So] Source:Acta Paediatr;105(11):1259-1260, 2016 Nov.
[Is] ISSN:1651-2227
[Cp] País de publicação:Norway
[La] Idioma:eng
[Mh] Termos MeSH primário: Lactente Extremamente Prematuro/fisiologia
Estudos Multicêntricos como Assunto/ética
Seleção de Pacientes
Ensaios Clínicos Controlados Aleatórios como Assunto/ética
Equipolência Terapêutica
[Mh] Termos MeSH secundário: Circulação Cerebrovascular/fisiologia
Seres Humanos
Recém-Nascido
Monitorização Fisiológica/métodos
Estudos Multicêntricos como Assunto/métodos
Consumo de Oxigênio
Ensaios Clínicos Controlados Aleatórios como Assunto/métodos
Espectrofotometria Infravermelho/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160819
[St] Status:MEDLINE
[do] DOI:10.1111/apa.13549


  6 / 155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27211932
[Au] Autor:Samson P; Waters EA; Meyers B; Politi MC
[Ad] Endereço:Division of Cardiothoracic Surgery, Section of Thoracic Surgery, Washington University, St. Louis, Missouri.
[Ti] Título:Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer.
[So] Source:Ann Thorac Surg;101(6):2049-52, 2016 Jun.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Shared decision making is a dynamic clinical process by which the provider assists the patient in choosing between more than one treatment option for a given condition. Here, we explore what the shared decision making and risk communication process could look like in the setting of a high-risk patient with clinical stage I non-small cell lung cancer who is potentially eligible for either segmentectomy or stereotactic body radiation therapy. We highlight clinical tools that can be used during the shared decision making and risk communication process in a stepwise manner to identify patient preferences and values to assist in making a tailored treatment decision.
[Mh] Termos MeSH primário: Carcinoma Pulmonar de Células não Pequenas/psicologia
Tomada de Decisões
Consentimento Livre e Esclarecido
Neoplasias Pulmonares/psicologia
Relações Médico-Paciente
[Mh] Termos MeSH secundário: Carcinoma Pulmonar de Células não Pequenas/radioterapia
Carcinoma Pulmonar de Células não Pequenas/cirurgia
Comportamento de Escolha
Técnicas de Apoio para a Decisão
Seres Humanos
Neoplasias Pulmonares/radioterapia
Neoplasias Pulmonares/cirurgia
Preferência do Paciente
Pneumonectomia/psicologia
Guias de Prática Clínica como Assunto
Radiocirurgia/psicologia
Risco
Medição de Risco
Equipolência Terapêutica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160524
[St] Status:MEDLINE


  7 / 155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27084665
[Au] Autor:Braunstein LZ; Warren LE
[Ad] Endereço:Harvard Radiation Oncology Program, Boston, Massachusetts.
[Ti] Título:Policy Implications of Proton Radiation Therapy: Toward an Evidence-Based Approach for Implementing Novel Oncologic Technologies.
[So] Source:Int J Radiat Oncol Biol Phys;95(1):560-1, 2016 May 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Ensaios Clínicos Fase II como Assunto
Consenso
Medicina Baseada em Evidências
Terapia com Prótons
[Mh] Termos MeSH secundário: Eficiência
Seres Humanos
Terapia com Prótons/economia
Mecanismo de Reembolso
Equipolência Terapêutica
[Pt] Tipo de publicação:LETTER
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160416
[Lr] Data última revisão:
160416
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160417
[St] Status:MEDLINE


  8 / 155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26764579
[Au] Autor:Mannarino CN; Faustino EV
[Ad] Endereço:Yale-New Haven Hospital, New Haven, CT 06510. Electronic address: candace.mannarino@yale.edu.
[Ti] Título:Clinical equipoise on prophylaxis against catheter-associated thrombosis in critically ill children.
[So] Source:J Crit Care;32:26-30, 2016 Apr.
[Is] ISSN:1557-8615
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: In preparation for a randomized controlled trial of prophylaxis against catheter-associated deep venous thrombosis in critically ill children, we aimed to determine clinical equipoise, defined as willingness to randomize children, among pediatric critical care physicians. MATERIALS AND METHODS: We conducted a cross-sectional, self-administered electronic survey of pediatric critical care physicians in the United States. The survey focused on the effect of child's age, presence of a central venous catheter, and risk (ie, presence of coagulopathy or recent surgery) and presence of bleeding on their willingness to randomize children to an anticoagulant or placebo. RESULTS: Responses from 239 (33.0%) of 725 physicians were analyzed. Respondents were willing to randomize children 1 month or older in the presence of a catheter but only those older than 13 years in the absence of a catheter. For children with coagulopathy, they would randomize those with international normalized ratio less than or equal to 2.0, partial thromboplastin time less than or equal to 50 seconds, and platelet count greater than or equal to 50000/mm(3). Respondents were willing to randomize children 2 days after most types of surgery and after 1 to 5 days of a bleeding event. CONCLUSIONS: Clinical equipoise on prophylaxis against catheter-associated thrombosis exists among pediatric critical care physicians, which ethically justifies conducting a randomized controlled trial.
[Mh] Termos MeSH primário: Anticoagulantes/administração & dosagem
Cateterismo Venoso Central/efeitos adversos
Cateteres Venosos Centrais/efeitos adversos
Estado Terminal
Pediatras/estatística & dados numéricos
Profilaxia Pré-Exposição
Equipolência Terapêutica
Trombose/prevenção & controle
[Mh] Termos MeSH secundário: Anticoagulantes/efeitos adversos
Criança
Estudos Transversais
Feminino
Pesquisas sobre Serviços de Saúde
Seres Humanos
Lactente
Coeficiente Internacional Normatizado
Masculino
Tempo de Tromboplastina Parcial
Ensaios Clínicos Controlados Aleatórios como Assunto
Risco
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anticoagulants)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160115
[St] Status:MEDLINE


  9 / 155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26730797
[Au] Autor:Beattie JM; Huxtable R
[Ad] Endereço:aHeart of England NHS Foundation Trust, Heartlands Hospital, Birmingham bCentre for Ethics in Medicine, School of Social and Community Medicine, University of Bristol, UK.
[Ti] Título:Implantable cardioverter defibrillator deactivation: a precautionary approach to therapeutic equipoise?
[So] Source:Curr Opin Support Palliat Care;10(1):5-7, 2016 Mar.
[Is] ISSN:1751-4266
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Desfibriladores Implantáveis/ética
Insuficiência Cardíaca/terapia
Equipolência Terapêutica
Incerteza
[Mh] Termos MeSH secundário: Insuficiência Cardíaca/mortalidade
Seres Humanos
Medição de Risco
[Pt] Tipo de publicação:EDITORIAL
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160106
[St] Status:MEDLINE
[do] DOI:10.1097/SPC.0000000000000191


  10 / 155 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26545204
[Au] Autor:Turner D; Koletzko S; Griffiths AM; Hyams J; Dubinsky M; de Ridder L; Escher J; Lionetti P; Cucchiara S; Lentze MJ; Koletzko B; van Rheenen P; Russell RK; Mack D; Veereman G; Vermeire S; Ruemmele F
[Ad] Endereço:*European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), Warsaw, Poland †European Crohn's and Colitis Organization (ECCO), Vienna, Austria ‡Global Pediatric IBD Network (PIBDnet) §Canadian Children IBD Network (a joint partnership of the Canadian Institutes of Health Research and the CH.I.L.D. Foundation), Toronto, ON, Canada ||Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel ¶Ludwig-Maximilians-University of Munich, Dr von Hauner Children's Hospital, University of Munich Medical Center-Klinikum der Universität München, München, Germany #The Hospital for Sick Children, University of Toronto, ON, Canada **Connecticut Children's Medical Center, Hartford ††Department of Pediatrics, Feinstein IBD Center, Icahn School of Medicine, Mount Sinai, New York, NY ‡‡Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands §§Department Neurofarba, University of Florence-Meyer Hospital, Florence |||| "La Sapienza" University of Rome, Rome, Italy ¶¶Department of Pediatrics, Children's Hospital Medical Center, University Hospitals, Bonn, Germany ##University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands ***Royal Hospital for Children, Glasgow, UK †††Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada ‡‡‡Children's University Hospital, Brussels §§§University Hospitals Gasthuisberg, Leuven, Belgium ||||||Hôpital Necker-Enfants Malades, Paris, France.
[Ti] Título:Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network.
[So] Source:J Pediatr Gastroenterol Nutr;62(1):183-7, 2016 Jan.
[Is] ISSN:1536-4801
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Performing well-designed and ethical trials in pediatric inflammatory bowel diseases (IBD) is a priority to support optimal therapy and reduce the unacceptable long lag between adult and pediatric drug approval. Recently, clinical trials in children have been incorporating placebo arms into their protocols under conditions that created controversy. Therefore, 4 organizations (the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; European Crohn's and Colitis Organization; the Canadian Children IBD Network; and the Global Pediatric IBD Network) jointly provide a statement on the role of placebo in pediatric IBD trials. Consensus was achieved by 94 of 100 (94%) voting committees' members that placebo should only be used if there is genuine equipoise between the active treatment and placebo; for example, this may be considered in trials of drugs with new mechanisms of action without existing adult data, especially when proven effective alternatives do not exist outside the trial. Placebo may also be used in situations where it is an "add-on" to an effective therapy or to evaluate exit-strategies of maintenance therapy after long-term deep remission. It has been, however, agreed that no child enrolled in a trial should receive a known inferior treatment both within and outside the trial. This also includes withholding therapy in children who show clinical response after a short induction therapy. Given the similarity between pediatric and adult IBD regarding pathophysiology and response to treatments, drugs generally cannot be considered being in genuine equipoise with placebo if it has proven efficacy in adults. Continued collaboration of all stakeholders is needed to facilitate drug development and evaluation in pediatric IBD.
[Mh] Termos MeSH primário: Ensaios Clínicos como Assunto/normas
Experimentação Humana/normas
Doenças Inflamatórias Intestinais/tratamento farmacológico
Placebos/normas
Projetos de Pesquisa/normas
[Mh] Termos MeSH secundário: Canadá
Criança
Ensaios Clínicos como Assunto/métodos
Consenso
Drogas em Investigação/normas
Europa (Continente)
Seres Humanos
Equipolência Terapêutica
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drugs, Investigational); 0 (Placebos)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151225
[Lr] Data última revisão:
151225
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151107
[St] Status:MEDLINE
[do] DOI:10.1097/MPG.0000000000001024



página 1 de 16 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde